Mounjaro's price increase in 2025: what actually changed and why it matters

Why did Mounjaro's UK price go up in September 2025?

Eli Lilly set a new UK list price for tirzepatide (Mounjaro) from 1 September 2025, with the most significant rise at the higher doses. As widely reported at the time, the top-dose pen's list price moved from roughly £122 to roughly £330 for a four-week supply. Lower doses saw smaller but still material increases. Eli Lilly has not made a detailed public statement on its rationale beyond standard pricing decisions, but the September 2025 change is now the pricing floor for every legitimate UK supplier.

It is worth being direct: any private clinic or pharmacy offering Mounjaro at prices substantially below that new list price should prompt serious questions about the supply chain. Genuine tirzepatide sourced through the licensed UK supply chain cannot be sold below cost. Mounjaro remains a Black Triangle medicine under additional MHRA monitoring, which means its provenance matters as much as its price.

The price change at the starter dose drew particular attention because many patients begin treatment at 2.5mg and stay there for the first four weeks. Even at the lower end of the range, private costs climbed. If you are comparing quotes, make sure each one refers to a specific dose, a headline figure without a dose attached tells you very little.

What does the UK private market typically charge after the increase?

Private Mounjaro prices in the UK since September 2025 have typically ranged from roughly £149 to £375 per four-week pen, depending on the dose and the provider. These are widely-reported figures, and individual providers price within that band according to their own cost structures and what they bundle in. The 5mg dose price increase sits in the middle of the range and is a common reference point because it is where many patients land after titration from the starter dose.

What those headline numbers often do not include: the consultation fee, the prescription fee, delivery, and any follow-up clinical support. Some providers list the medicine price and add those separately. A quote that looks lower upfront can reach the same total (or exceed it) by the time everything is accounted for. That is not a criticism of any particular provider, just an accurate description of how private medicine pricing works in the UK.

For context on whether your dose specifically has been affected, the full breakdown of the Mounjaro price increase covers the range in detail. The Mounjaro cost page also sets out what to look for when comparing providers.

Did the Mounjaro NHS price increase too, and does that affect private patients?

The September 2025 price increase applies to the private market. NHS prescribing operates under separate reimbursement arrangements, and the Mounjaro price increase 2025 NHS impact is primarily felt in commissioning budgets rather than in what individual NHS patients pay. The NHS does not charge patients for tirzepatide when it is prescribed through qualifying routes, but access is tightly phased. NICE's appraisal of tirzepatide (TA1026) sets the clinical thresholds, and NHS England is rolling out access in stages, with the broadest eligibility not expected until 2027.

For private patients, the NHS pricing structure is largely irrelevant to the bill they receive, what matters is the licensed supply chain and what a private provider bundles into their fee. Some people choosing private treatment have found that the NHS criteria do not yet cover their situation, or that waiting lists are too long. Neither is unusual. The honest answer is that private treatment costs more than it did before September 2025, and any provider suggesting otherwise is worth scrutinising.

If you are uncertain whether you meet NHS or private eligibility, the weight-loss treatment overview covers both routes clearly.

Is the cheapest Mounjaro listing after the price increase actually the right choice?

After a price increase, the instinct to find the lowest quote is understandable. But for a prescription medicine, the lowest price is the wrong starting point. The MHRA has warned repeatedly about counterfeit tirzepatide pens entering the UK, fake products that have been seized in large quantities and, in some cases, caused harm. A listing that appears to undercut the licensed supply chain is not a bargain; it is a signal that something is wrong. You can verify any online pharmacy's registration on the GPhC register, and you should do so before placing any order.

nume is not the cheapest option, and we say that plainly. Cheapest is not a contest we entered. What the price includes at nume: a free consultation reviewed the same day by a GPhC-registered Independent Prescriber, the prescription, the treatment itself, and free next-working-day delivery by DPD, tracked to your door in a plain box, nothing on the outside to indicate what's inside. Seven-day aftercare from a clinical team is included too, with no subscription and no repeat order processed without a fresh clinical review.

The right question after a price increase is not who charges least. It is who provides genuine medicine, genuine clinical oversight, and genuine support, reliably. Our clinical team is named and qualified; you can read about them before you start. If you have questions about how much Mounjaro lowers blood sugar, or anything else about your treatment, our team is reachable. And if you are ready to find out whether treatment is suitable for you, speak to our prescribers through a free consultation.